Here is the reason for the healthy performance of Ascendis Pharma A/S (ASND)

TimesSquare Capital Management, an equity investment management firm, released its third quarter letter to investors titled “US Mid Cap Growth Strategy”. A copy of it can be downloaded here. In the third quarter, the strategy returned -0.21% (net), compared to -0.65% for the Russell Midcap Growth Index. Strength in the consumer discretionary, energy, financials, industrials, information technology and materials sectors contributed to the strategy’s performance during the quarter. Additionally, please see the fund’s top five holdings for its top picks in 2022.

TimesSquare Capital highlighted stocks like Ascendis Pharma A/S (NASDAQ:ASND) in the Q3 2022 Investor Letter. Based in Hellerup, Denmark, Ascendis Pharma A/S (NASDAQ: ASND) is a biopharmaceutical company. On December 23, 2022, Ascendis Pharma A/S stock (NASDAQ:ASND) closed at $119.09 per share. The one-month return of Ascendis Pharma A/S (NASDAQ:ASND) was 2.72% and its shares have lost 14.52% of their value over the past 52 weeks. Ascendis Pharma A/S (NASDAQ: ASND) has a market capitalization of $6.791 billion.

TimesSquare Capital made the following comment about Ascendis Pharma A/S (NASDAQ:ASND) in its Q3 2022 Letter to Investors:

Tonhom1009/Shutterstock.com

Ascendis Pharma A/S (NASDAQ: ASND) is not on our list of 30 most popular stocks among hedge funds. According to our database, 34 hedge fund portfolios held Ascendis Pharma A/S (NASDAQ:ASND) at the end of the third quarter, up from 26 in the prior quarter.

The story continues

We discussed Ascendis Pharma A/S (NASDAQ: ASND) in another article and shared the best Guru stocks to buy. Additionally, please see our Letters to Hedge Fund Investors Q3 2022 page for more letters from hedge fund investors and other leading investors.

Suggested items:

Disclosure: none. This article is originally published on Insider Monkey.